Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

tual results may vary once the final and quality-controlled verification of data and analyses has been completed, the expense and uncertainty of obtaining regulatory approval, including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory approval is obtained, therapeutic products are generally subject to: stringent on-going governmental regulation, challenges in gaining market acceptance, and competition. Neurochem does not undertake any obligation to publicly update its forward-looking statements, whether as a result of new information, future events, or otherwise. Please see the Annual Information Form for further risk factors that might affect the Company and its business.

    For further information, please contact:


    Lise Hebert, PhD                          Tel: (450) 680-4572

    Vice President, Corporate Communications  

lhebert@neurochem.com

CONTACT: Lise Hebert, PhD, Vice President, Corporate Communications, (450)680-4572, lhebert@neurochem.com

Ticker Symbol: (:NRM.),(:NRMX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:10/22/2014)... -- CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today that James Patrick ... been elected to the Company,s Board of Directors, effective ... , Executive Chairman of CryoLife, stated, "Since joining the Company ... leader who is well positioned to maximize CryoLife,s potential. ...
(Date:10/22/2014)... SAN DIEGO , Oct. 21, 2014 /PRNewswire/ ... announced today the latest genomics research centers to ... the Salk Institute, the National Cancer Institute (NCI), ... National Sequencing Center). Before Irys, obtaining a comprehensive ... because next generation sequencing (NGS) does not deliver ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
... Inc. announced today that it has raised $19.2 million ... GBS Venture Partners and BioPacificVentures participated in the round. ... from additional investors in a second closing, scheduled for ... us to take essential steps for the development of ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... into a multi-year research collaboration agreement through the Stanford ... collaborative and innovative research projects in the early phases ... Dr. Paul Chew, Senior Vice President, U.S. Chief Science ...
Cached Medicine Technology:CoDa Therapeutics Closes $19 Million Series B Financing Round 2CoDa Therapeutics Closes $19 Million Series B Financing Round 3CoDa Therapeutics Closes $19 Million Series B Financing Round 4Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 2Sanofi-aventis Enters into Collaboration Agreement with Stanford University Bio-X to Focus on Early-Stage Scientific Research 3
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In ... in the face, it certainly can be difficult to choose ... an extra favor by doing it the healthy way? Set ... listen to your body, exercise regularly, and choose foods with ... losing weight; you need to exercise more and eat less. ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... The U.S. Pharmacopeial (USP) Convention is pleased ... from the Cooperation on International Traceability in Analytical ... on Metrology in Chemistry in 2008. , USP,s ... Reference Standards Program: Certified Reference Materials," was published ...
... NovoCure Ltd. presented results yesterday evaluating the Novo-TTF ... trial that showed the device enhanced the efficacy ... multiforme (GBM) patients. When used in combination with ... that uses low intensity alternating electric fields to ...
... QC, Nov. 24 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; ... will host a webcast presentation on Tuesday, December 16, ... senior management team will discuss the product profile, clinical ... novel once-daily formulation of trazodone (DDS-04A), a serotonin antagonist ...
... 24 Availity, L.L.C. was,recognized as the ... Site in the,Business/Process Improvement Applications or Products ... Conference November 11 in Orlando, Florida. The,eHealthcare ... & Trends,a leading internet publication and online ...
... new treatments, researchers say , , MONDAY, Nov. 24 (HealthDay News) ... system and blood vessels may contribute to epileptic seizures, new ... case, such interactions may be a target for new treatments ... the Nov. 23 issue of Nature Medicine . , ...
... 24 Aurora Health Care Ventures has been,granted ... Inc. for Aurora Pharmacy and a health-oriented retail ... The accreditation applies to Aurora,s 130 retail pharmacies, ... retail store inside Aurora,St. Luke,s Medical Center in ...
Cached Medicine News:Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 2Health News:Studies show novel device may enhance chemotherapy treatment in brain tumors 3Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 2Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 3Health News:Labopharm to host webcast presentation on novel trazodone formulation for treatment of major depressive disorder 4Health News:Availity Achieves 2008 eHealthcare Leadership Award 2Health News:Clue to Cause of Epileptic Seizures Discovered 2Health News:Accreditation Commission for Health Care Accredits Aurora Pharmacy Sites, Retail Store 2
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Black multi-pinhole occluder...
6 inch hand held occlcuder with 49 holes...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: